Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD issues advice on cascade use of antibiotics
antibiotics
VMD has released a position statement in response to concerns over antibiotic use on the cascade.
Vets report conflict between responsible use and legal requirements

The Veterinary Medicines Directorate (VMD) is calling for professional bodies, veterinary schools and research institutes to work together to help vets make a more informed choice when prescribing antibiotics on the cascade.

Veterinary surgeons have raised concerns with the VMD about the difficulty of balancing the responsible use of antibiotics with legal requirements to prescribe UK authorised medicines before applying the cascade.

According to the VMD, vets are reporting an increasingly common challenge - where there is an authorised medicine that is a critically important antibiotic (CIA) and/or is not narrow spectrum. Under legislative requirements, this should be used as a first line treatment, rather than an unauthorised, non-CIA drug.

However, in some cases, other products authorised for use in other EU member states may be more appropriate in terms of the responsible use of antibiotics.

In response to these concerns, the VMD has issued its position statement on prescribing antibiotics under the cascade.

On a case-by-case basis, the directorate says it is "justified" to to prescribe an antibiotic on the cascade to reduce the development of resistance.

Vets must demonstrate that they have considered the most appropriate active substance(s), formulation, posology, current patterns of resistance in their locality, awareness of how to reduce selection pressure and other factors, such as good biosecurity, husbandry, hygiene and avoidance of surgical sepsis.

VMD is calling for the industry to collaborate on compiling up-to-date evidence and guidance to help vets make an informed choice based on scientific evidence and peer reviewed data.

Vets are also advised to keep up-to-date with the latest guidance provided by organisations including the BVA, BSAVA, BEVA, Pig Veterinary Society and Responsible Use of Medicines in Agriculture.

For the full position statement, see the VMD website: http://www.vmd.defra.gov.uk/pdf/cascade.pdf

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.